Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pinterest

- PMLiVE

GSK’s malaria vaccine effects ‘modest’ in infants

Less than expected efficacy findings surprise researchers

- PMLiVE

Malaria charity calls up Ladbury PR to handle comms

Comes as Malaria No More UK partners with ITV’s I’m A Celebrity…Get Me Out Of Here

- PMLiVE

NICE to reverse approval for Novartis’ asthma drug Xolair

Draft guidance doesn't recommend omalizumab for severe asthma

Novartis building

Novartis says pipeline is “industry leading”

Touts 14 drug candidates with $1bn-plus sales potential

Novartis building

Novartis’ heart failure drug serelaxin meets targets

And FDA committee backs Signifor for Cushing's disease

Novartis building

EC approves extra tumour indication for Novartis’ Votubia

First drug approved in Europe for non-cancer tumours associated with TSC

Novartis building

Canada and Switzerland lift Novartis flu vaccines ban

Independent tests confirm safety following contamination fears

- PMLiVE

Novartis revives delayed Singapore biotech plans

Aims to have biotechnology facility up and running before 2017

- PMLiVE

Guide to gamification

How to execute digital: Using gaming as part of a pharma marketing campaign

Novartis building

France, Germany and Spain join list of countries banning Novartis vaccines

Flu vaccines Agrippal and Fluad withdrawn after some batches found to be contaminated

Novartis building

NICE backs Novartis’ Tobi Podhaler in cystic fibrosis

But draft guidance doesn't recommend Forest’s Colobreathe

- PMLiVE

Oxfam calls for end to malaria drug access scheme

Charity says Affordable Medicines Facility for malaria is endangering lives

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links